EMA确认治疗光化性角化病的Picato凝胶存在致癌风险

2020-04-22 MedSci原创 MedSci原创

Janice

医生/ 主治医师

欧洲药品管理局的安全委员会已确认，治疗皮肤病光化性角化病的Picato (Ingenol Mebutate)凝胶可能会增加患皮肤癌的风险。

欧洲药品管理局的安全委员会（PRAC）已确认，用于治疗皮肤病光化性角化病的Picato(Ingenol Mebutate)凝胶可能会增加患皮肤癌的风险。

在对所有可用数据进行安全审查之后，该机构得出结论，该药物的风险大于其益处。

将Picato与另一种用于治疗光化性角化病的药物imiquimod进行了比较，结果显示在用Picato治疗的皮肤区域，皮肤癌（尤其是鳞状细胞癌）的发生率更高。

欧盟已撤销Picato的销售许可，并提醒接受过该药物治疗的患者发现皮肤异常变化或生长的情况，需要及时寻求医疗咨询。

光化性角化病是日光长期照射或电离辐射刺激引致的表皮角化过度疾病，也称为日光性角化病或老年性角化病，是最常见的一种上皮性癌前期损害。

原始出处：

http://www.pharmatimes.com/news/ema_confirms_skin_cancer_risk_with_leos_picato_1338594

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (8)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1648840, encodeId=290716488401d, content=<a href='/topic/show?id=d7a328e40fd' target=_blank style='color:#2F92EE;'>#光化性角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28740, encryptionId=d7a328e40fd, topicName=光化性角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a8a23689373, createdName=jinweidong, createdTime=Tue Mar 02 14:13:17 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023318, encodeId=649b20233182b, content=<a href='/topic/show?id=bb29865199d' target=_blank style='color:#2F92EE;'>#致癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86519, encryptionId=bb29865199d, topicName=致癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 19 06:13:17 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061931, encodeId=15aa20619312a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Mar 20 18:13:17 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317562, encodeId=e94b131e56219, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371002, encodeId=deb613e100240, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461056, encodeId=58f414610567d, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623597, encodeId=2a2b162359e83, content=<a href='/topic/show?id=a323909163b' target=_blank style='color:#2F92EE;'>#角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90916, encryptionId=a323909163b, topicName=角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10a720562694, createdName=guihongzh, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382071, encodeId=a0353820e187, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ca45017967, createdName=946207329, createdTime=Wed Apr 22 18:09:27 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
2021-03-02 jinweidong

#光化性角化病#

79 0
[GetPortalCommentsPageByObjectIdResponse(id=1648840, encodeId=290716488401d, content=<a href='/topic/show?id=d7a328e40fd' target=_blank style='color:#2F92EE;'>#光化性角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28740, encryptionId=d7a328e40fd, topicName=光化性角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a8a23689373, createdName=jinweidong, createdTime=Tue Mar 02 14:13:17 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023318, encodeId=649b20233182b, content=<a href='/topic/show?id=bb29865199d' target=_blank style='color:#2F92EE;'>#致癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86519, encryptionId=bb29865199d, topicName=致癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 19 06:13:17 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061931, encodeId=15aa20619312a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Mar 20 18:13:17 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317562, encodeId=e94b131e56219, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371002, encodeId=deb613e100240, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461056, encodeId=58f414610567d, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623597, encodeId=2a2b162359e83, content=<a href='/topic/show?id=a323909163b' target=_blank style='color:#2F92EE;'>#角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90916, encryptionId=a323909163b, topicName=角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10a720562694, createdName=guihongzh, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382071, encodeId=a0353820e187, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ca45017967, createdName=946207329, createdTime=Wed Apr 22 18:09:27 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
2021-02-19 lq1767

#致癌风险#

77 0
[GetPortalCommentsPageByObjectIdResponse(id=1648840, encodeId=290716488401d, content=<a href='/topic/show?id=d7a328e40fd' target=_blank style='color:#2F92EE;'>#光化性角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28740, encryptionId=d7a328e40fd, topicName=光化性角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a8a23689373, createdName=jinweidong, createdTime=Tue Mar 02 14:13:17 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023318, encodeId=649b20233182b, content=<a href='/topic/show?id=bb29865199d' target=_blank style='color:#2F92EE;'>#致癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86519, encryptionId=bb29865199d, topicName=致癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 19 06:13:17 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061931, encodeId=15aa20619312a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Mar 20 18:13:17 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317562, encodeId=e94b131e56219, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371002, encodeId=deb613e100240, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461056, encodeId=58f414610567d, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623597, encodeId=2a2b162359e83, content=<a href='/topic/show?id=a323909163b' target=_blank style='color:#2F92EE;'>#角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90916, encryptionId=a323909163b, topicName=角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10a720562694, createdName=guihongzh, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382071, encodeId=a0353820e187, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ca45017967, createdName=946207329, createdTime=Wed Apr 22 18:09:27 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
2021-03-20 docwu2019

#癌风险#

106 0
[GetPortalCommentsPageByObjectIdResponse(id=1648840, encodeId=290716488401d, content=<a href='/topic/show?id=d7a328e40fd' target=_blank style='color:#2F92EE;'>#光化性角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28740, encryptionId=d7a328e40fd, topicName=光化性角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a8a23689373, createdName=jinweidong, createdTime=Tue Mar 02 14:13:17 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023318, encodeId=649b20233182b, content=<a href='/topic/show?id=bb29865199d' target=_blank style='color:#2F92EE;'>#致癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86519, encryptionId=bb29865199d, topicName=致癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 19 06:13:17 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061931, encodeId=15aa20619312a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Mar 20 18:13:17 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317562, encodeId=e94b131e56219, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371002, encodeId=deb613e100240, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461056, encodeId=58f414610567d, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623597, encodeId=2a2b162359e83, content=<a href='/topic/show?id=a323909163b' target=_blank style='color:#2F92EE;'>#角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90916, encryptionId=a323909163b, topicName=角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10a720562694, createdName=guihongzh, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382071, encodeId=a0353820e187, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ca45017967, createdName=946207329, createdTime=Wed Apr 22 18:09:27 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
2020-04-24 fengyi812

#EMA#

94 0
[GetPortalCommentsPageByObjectIdResponse(id=1648840, encodeId=290716488401d, content=<a href='/topic/show?id=d7a328e40fd' target=_blank style='color:#2F92EE;'>#光化性角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28740, encryptionId=d7a328e40fd, topicName=光化性角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a8a23689373, createdName=jinweidong, createdTime=Tue Mar 02 14:13:17 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023318, encodeId=649b20233182b, content=<a href='/topic/show?id=bb29865199d' target=_blank style='color:#2F92EE;'>#致癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86519, encryptionId=bb29865199d, topicName=致癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 19 06:13:17 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061931, encodeId=15aa20619312a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Mar 20 18:13:17 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317562, encodeId=e94b131e56219, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371002, encodeId=deb613e100240, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461056, encodeId=58f414610567d, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623597, encodeId=2a2b162359e83, content=<a href='/topic/show?id=a323909163b' target=_blank style='color:#2F92EE;'>#角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90916, encryptionId=a323909163b, topicName=角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10a720562694, createdName=guihongzh, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382071, encodeId=a0353820e187, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ca45017967, createdName=946207329, createdTime=Wed Apr 22 18:09:27 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
2020-04-24 jambiya

#致癌#

84 0
[GetPortalCommentsPageByObjectIdResponse(id=1648840, encodeId=290716488401d, content=<a href='/topic/show?id=d7a328e40fd' target=_blank style='color:#2F92EE;'>#光化性角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28740, encryptionId=d7a328e40fd, topicName=光化性角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a8a23689373, createdName=jinweidong, createdTime=Tue Mar 02 14:13:17 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023318, encodeId=649b20233182b, content=<a href='/topic/show?id=bb29865199d' target=_blank style='color:#2F92EE;'>#致癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86519, encryptionId=bb29865199d, topicName=致癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 19 06:13:17 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061931, encodeId=15aa20619312a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Mar 20 18:13:17 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317562, encodeId=e94b131e56219, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371002, encodeId=deb613e100240, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461056, encodeId=58f414610567d, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623597, encodeId=2a2b162359e83, content=<a href='/topic/show?id=a323909163b' target=_blank style='color:#2F92EE;'>#角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90916, encryptionId=a323909163b, topicName=角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10a720562694, createdName=guihongzh, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382071, encodeId=a0353820e187, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ca45017967, createdName=946207329, createdTime=Wed Apr 22 18:09:27 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
2020-04-24 lishizhe

#凝胶#

125 0
[GetPortalCommentsPageByObjectIdResponse(id=1648840, encodeId=290716488401d, content=<a href='/topic/show?id=d7a328e40fd' target=_blank style='color:#2F92EE;'>#光化性角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28740, encryptionId=d7a328e40fd, topicName=光化性角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a8a23689373, createdName=jinweidong, createdTime=Tue Mar 02 14:13:17 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023318, encodeId=649b20233182b, content=<a href='/topic/show?id=bb29865199d' target=_blank style='color:#2F92EE;'>#致癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86519, encryptionId=bb29865199d, topicName=致癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 19 06:13:17 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061931, encodeId=15aa20619312a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Mar 20 18:13:17 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317562, encodeId=e94b131e56219, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371002, encodeId=deb613e100240, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461056, encodeId=58f414610567d, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623597, encodeId=2a2b162359e83, content=<a href='/topic/show?id=a323909163b' target=_blank style='color:#2F92EE;'>#角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90916, encryptionId=a323909163b, topicName=角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10a720562694, createdName=guihongzh, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382071, encodeId=a0353820e187, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ca45017967, createdName=946207329, createdTime=Wed Apr 22 18:09:27 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
2020-04-24 guihongzh

#角化病#

145 0
[GetPortalCommentsPageByObjectIdResponse(id=1648840, encodeId=290716488401d, content=<a href='/topic/show?id=d7a328e40fd' target=_blank style='color:#2F92EE;'>#光化性角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28740, encryptionId=d7a328e40fd, topicName=光化性角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a8a23689373, createdName=jinweidong, createdTime=Tue Mar 02 14:13:17 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023318, encodeId=649b20233182b, content=<a href='/topic/show?id=bb29865199d' target=_blank style='color:#2F92EE;'>#致癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86519, encryptionId=bb29865199d, topicName=致癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 19 06:13:17 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061931, encodeId=15aa20619312a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Mar 20 18:13:17 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317562, encodeId=e94b131e56219, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371002, encodeId=deb613e100240, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461056, encodeId=58f414610567d, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623597, encodeId=2a2b162359e83, content=<a href='/topic/show?id=a323909163b' target=_blank style='color:#2F92EE;'>#角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90916, encryptionId=a323909163b, topicName=角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10a720562694, createdName=guihongzh, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382071, encodeId=a0353820e187, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ca45017967, createdName=946207329, createdTime=Wed Apr 22 18:09:27 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
2020-04-22 946207329

感谢分享

177 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

EMA确认治疗光化性角化病的Picato凝胶存在致癌风险

相关资讯

科室

工具

服务